참고문헌
- Cariaga-Martinez AE, Lopez-Ruiz P, Nombela-Blanco MP, et al (2013). Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells. Cell Signal, 25, 1586-97. https://doi.org/10.1016/j.cellsig.2013.03.019
-
Carstens JL, Shahi P, Van Tsang S, et al (2014). FGFR1- WNT-TGF-
$\beta$ signaling in prostate cancer mouse models recapitulates human reactive Stroma. Cancer Res, 74, 609-20. https://doi.org/10.1158/0008-5472.CAN-13-1093 - Dreicer R (2014). How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. Can J Urol, 21, 93-7.
- He M, Liu Y, Deng X, et al (2013). Down-regulation of miR-200b-3p by low p73 contributes to the androgenindependence of prostate cancer cells. Prostate, 73, 1048-56. https://doi.org/10.1002/pros.22652
- Heidenreich A, Bastian PJ, Bellmunt J, et al (2014). EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol, 65, 467-79. https://doi.org/10.1016/j.eururo.2013.11.002
- Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
- Kahn B, Collazo J, Kyprianou N (2014). Androgen receptor as a driver of therapeutic resistance in advancedprostate cancer. Int J Biol Sci, 10, 588-95. https://doi.org/10.7150/ijbs.8671
- Mukherji D, Pezaro CJ, Shamseddine A, et al (2013). New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat Rev, 39, 578-83. https://doi.org/10.1016/j.ctrv.2012.12.004
- Nemes A , Tomuleasa C, Kacso G (2014). The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments. J BUON, 19, 357-64.
- Nyquist MD, Li Y, Hwang TH, et al (2013). TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci USA, 110, 17492-7. https://doi.org/10.1073/pnas.1308587110
- Shi X, Gipp J, Dries M, et al (2014). Prostate progenitor cells proliferate in response to castration. Stem Cell Res, 13, 154-63. https://doi.org/10.1016/j.scr.2014.04.005
- Sooriakumaran P, Nyberg T, Akre O, et al (2014). Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. Brit Med J, 348, 1502. https://doi.org/10.1136/bmj.g1502
- Wang X-Y, Hao J-W, Zhou R-J, et al (2013). Meta-analysis of gene expression data identifies causal genes for prostate cancer. Asian Pac J Cancer Prev, 14, 457-61. https://doi.org/10.7314/APJCP.2013.14.1.457
- Xu WP, Shen E, Bai WK, et al (2014). Enhanced antitumor effects of low-frequency ultrasound and microbubbles in combination with simvastatin by downregulating caveolin-1 in prostatic DU145 cells. Oncol Lett, 7, 2142-8.
- Zhang K, Zhang X (2014). Treatment strategies for locally advanced prostate cancer. Chin Med J (Engl), 127, 957-60.
- Hu Z-H, Lin Y-W, Xu X, et al (2013). Genetic polymorphisms of glutathione s-transferase m1 and prostate cancer risk in Asians: a meta-analysis of 18 studies. Asian Pac J Cancer Prev, 14, 393-8. https://doi.org/10.7314/APJCP.2013.14.1.393
피인용 문헌
- Characterization of long non-coding RNA expression profiles in lymph node metastasis of early-stage cervical cancer vol.35, pp.6, 2016, https://doi.org/10.3892/or.2016.4715
- DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence vol.75, pp.15, 2015, https://doi.org/10.1002/pros.23052
- Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2 vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5070
- Prostate cancer downregulated SIRP-α modulates apoptosis and proliferation through p38-MAPK/NF-κB/COX-2 signaling vol.13, pp.6, 2017, https://doi.org/10.3892/ol.2017.6070